BrainStorm announces Nasdaq delisting and transition to OTCQB
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 17 2025
0mins
Delisting Notification: BrainStorm Cell Therapeutics has received a notification from Nasdaq that its common stock will be delisted due to non-compliance with the minimum shareholder equity requirement, effective July 18.
Transition to OTCQB: The company has secured approval to have its shares quoted on the OTCQB Venture Market under the same symbol, BCLI, starting July 18 or shortly thereafter.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like undefined with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
